Potential New Treatment for Alpha-1 Antitrypsin Deficiency
Trial Objectives
Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.
Enrollment
Active Clinical Trials Closed to Recruitment
Who Can Participate
People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.
Age: 18-80 Gender: Any
Estimated Time Commitment
Not Specified
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Kristina Eliopoulos
303.270.2622
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Institutes of Health, University of Alabama at Birmingham
Principal Investigators
Robert A. Sandhaus, MD, PhD, FCCP